Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
FDA offers a research opportunity in the Office of Translational Sciences (OTS), OCP, DARS, CDER, located in Silver Spring, MD. A doctoral degree is required, and the appointment emphasizes data mining, regulatory science methods, and collaborative translational work in cardiovascular safety data analysis.
The program is full-time with a monthly stipend and potential manuscript authorship. The learning objectives include gaining knowledge of FDA regulatory policies, developing data mining and
U.S. Food and Drug Administration (FDA)
FDA-CDER-2026-0160
A research opportunity is available in the Office of Translational Sciences (OTS), Office of Clinical Pharmacology (OCP), Division of Applied Regulatory Science (DARS) at the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA), located in Silver Spring, Maryland. The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. These efforts cover more than just medicines.
This research opportunity supports data mining and database development efforts in the cardiovascular safety space, with a focus on advancing regulatory science through systematic analysis of nonclinical and clinical cardiotoxicity data. You will contribute to the development and curation of comprehensive databases designed to evaluate the current landscape of cardiovascular safety data used in drug development and regulatory decision-making.
You will investigate and apply advanced data mining techniques, statistical modeling, and computational tools to identify patterns, gaps, and trends across large datasets relevant to cardiac safety including human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) data, ion channel pharmacology, in vivo and clinical QT data, and other cardiotoxicity endpoints. Through this, you will collaborate with FDA scientists to analyze how real-world and experimental data can be leveraged to inform translational regulatory strategies.
This research will contribute to the development of innovative approaches for integrating large-scale cardiovascular safety datasets into the regulatory review process, advancing FDA's regulatory science mission and public health objectives.
You will gain comprehensive knowledge of FDA regulatory policies and regulations regarding the evaluation of safety and efficacy of new drugs, along with hands-on experience in regulatory science methodologies.
The mentor for this opportunity is Tromondae Feaster (Tromondae.Feaster@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.
September 1, 2026. Start date is flexible and will depend on a variety of factors.
The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.
The appointment is full time.
The participant will receive a monthly stipend commensurate with educational level and experience.
This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.
The qualified candidate should be currently pursuing or have received a doctoral degree in the one of the relevant fields.
Ashley
I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)